SAGE240719P10000
- 0.03
- 0.000.00%
Sage Therapeutics Newsroom
Sage Therapeutics/Biogen's Episodic Therapy Zuranolone Could Change MDD Treatment
Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names.
Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $18
Mizuho Securities analyst Uy Ear maintains $Sage Therapeutics(SAGE.US)$ with a hold rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 40.4%
Mizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Express News | Sage Therapeutics Inc : Mizuho Cuts Target Price to $16 From $18
Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, July 31, 2024 at 4:30 p.m. ET
Analyst Expectations For Sage Therapeutics's Future
In the last three months, 20 analysts have published ratings on Sage Therapeutics (NASDAQ:SAGE), offering a diverse range of perspectives from bullish to bearish.The table below provides a snapshot
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $18
JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $23 to $18.
J.P. Morgan Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Cuts Target Price to $18
J.P. Morgan analyst Anupam Rama maintains $Sage Therapeutics(SAGE.US)$ with a buy rating, and adjusts the target price from $23 to $18.According to TipRanks data, the analyst has a success rate of 47.
Express News | Sage Therapeutics Inc : JP Morgan Cuts Target Price to $18 From $23
Delta Air Lines Posts Downbeat Earnings, Joins United Airlines, American Airlines And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Thursday.Shares of Delta Air Lines, Inc. (NYSE:DAL) fell sharply in today's pre-market trading after the
Express News | Sage Therapeutics Inc : Leerink Partners Cuts Target Price to $15 From $22
RBC Cuts Price Target on Sage Therapeutics to $12 From $15, Keeps Sector Perform Rating
Sage Therapeutics (SAGE) has an average investment rating of hold among analysts polled by Capital IQ, with price targets ranging from $8 to $70.
Express News | Sage Therapeutics Inc : RBC Cuts Target Price to $12 From $15
H.C. Wainwright Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $25
H.C. Wainwright analyst Douglas Tsao maintains $Sage Therapeutics(SAGE.US)$ with a hold rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 37.8
SAGE Therapeutics: A Balanced Hold Rating Amidst Promising Zurzuvae Launch and Clinical Pipeline Prospects
Needham Reiterates Hold on Sage Therapeutics
Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Hold.
Needham Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Needham analyst Ami Fadia maintains $Sage Therapeutics(SAGE.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 43.9% and a total average return of 3.6% over the past
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew rec
19 Analysts Have This To Say About Sage Therapeutics
Across the recent three months, 19 analysts have shared their insights on Sage Therapeutics (NASDAQ:SAGE), expressing a variety of opinions spanning from bullish to bearish.The following table provide